Hanmi Pharm Rises 23.02% Amid Uptrend in Biosimilar (Generic Biopharmaceutical) Theme

On the 5th, the biosimilar (replicated biopharmaceutical) theme showed strength, rising 3.84% compared to the previous day, while Hanmi Pharm, which is attracting attention as a related stock, surged 23.02% compared to the previous day. Hanmi Pharm is known as a pharmaceutical company specializing in the production of prescription drugs.

[Graph] Major stock price changes in the biosimilar (replicated biopharmaceutical) theme



According to the analysis by Thinkpool Robo Algorithm RASSI, Hanmi Pharm ranked 6th out of 17 stocks in the quant financial ranking by exceeding the theme's average scores in growth, stability, and profitability. This can be interpreted as Hanmi Pharm having relatively high investment attractiveness compared to other stocks within the theme from a financial perspective.

[Table] Top stocks by financial scores within the theme


※ The quant financial score is the result of the robo algorithm's analysis based on each company's sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, and other factors.

※ This article was generated in real time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.